Isolation, Production and Characterization of Fully Human Monoclonal Antibodies Directed to Plasmodium Falciparum MSP10

Overview

Journal Malar J

Publisher Biomed Central

Specialty Tropical Medicine

Date 2015 Jul 16

PMID 26174014

Citations 16

Authors

Dominika J Maskus

Susanne Bethke

Melanie Seidel

Stephanie Kapelski

Otchere Addai-Mensah

Alexander Boes

Guven Edgu

Holger Spiegel

Andreas Reimann

Rainer Fischer

Stefan Barth

Torsten Klockenbring

Rolf Fendel

Affiliations

Soon will be listed here.

Abstract

Background: Semi-immunity against the malaria parasite is defined by a protection against clinical episodes of malaria and is partially mediated by a repertoire of inhibitory antibodies directed against the blood stage of Plasmodium falciparum, in particular against surface proteins of merozoites, the invasive form of the parasite. Such antibodies may be used for preventive or therapeutic treatment of P. falciparum malaria. Here, the isolation and characterization of novel human monoclonal antibodies (humAbs) for such applications is described.

Methods: B lymphocytes had been selected by flow cytometry for specificity against merozoite surface proteins, including the merozoite surface protein 10 (MSP10). After Epstein-Barr virus (EBV) transformation and identification of promising resulting lymphoblastoid cell lines (LCLs), human immunoglobulin heavy and light chain variable regions (Vh or Vl regions) were secured, cloned into plant expression vectors and transiently produced in Nicotiana benthamiana in the context of human full-size IgG1:κ. The specificity and the affinity of the generated antibodies were assessed by ELISA, dotblot and surface plasmon resonance (SPR) spectroscopy. The growth inhibitory activity was evaluated based on growth inhibition assays (GIAs) using the parasite strain 3D7A.

Results: Supernatants from two LCLs, 5E8 and 5F6, showed reactivity against the second (5E8) or first (5F6) epidermal growth factor (EGF)-like domain of MSP10. The isolated V regions were recombinantly expressed in their natural pairing as well as in combination with each other. The resulting recombinant humAbs showed affinities of 9.27 × 10(-7) M [humAb10.1 (H5F6:κ5E8)], 5.46 × 10(-9) M [humAb10.2 (H5F6:κ5F6)] and 4.34 × 10(-9) M [humAb10.3 (H5E8:κ5E8)]. In GIAs, these antibodies exhibited EC50 values of 4.1 mg/ml [95% confidence interval (CI) 2.6-6.6 mg/ml], 6.9 mg/ml (CI 5.5-8.6 mg/ml) and 9.5 mg/ml (CI 5.5-16.4 mg/ml), respectively.

Conclusion: This report describes a platform for the isolation of human antibodies from semi-immune blood donors by EBV transformation and their subsequent characterization after transient expression in plants. To our knowledge, the presented antibodies are the first humAbs directed against P. falciparum MSP10 to be described. They recognize the EGF-like folds of MSP10 and bind these with high affinity. Moreover, these antibodies inhibit P. falciparum 3D7A growth in vitro.

Citing Articles

Recent advances in immunotherapies against infectious diseases.

Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K Immunother Adv. 2024; 1(1):ltaa007.

PMID: 38626281 PMC: 7717302. DOI: 10.1093/immadv/ltaa007.

Identification and Characterization of Rhoptry Protein 35 (EtROP35).

Wang B, Zhao N, Sun J, Sun L, Li H, Wu Z Vet Sci. 2022; 9(9).

PMID: 36136681 PMC: 9505231. DOI: 10.3390/vetsci9090465.

Non-Invasive Antibody Assessment in Saliva to Determine SARS-CoV-2 Exposure in Young Children.

Heinzel C, Pinilla Y, Elsner K, Friessinger E, Mordmuller B, Kremsner P Front Immunol. 2021; 12:753435.

PMID: 34691072 PMC: 8531807. DOI: 10.3389/fimmu.2021.753435.

Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity.

Seidel-Greven M, Addai-Mensah O, Spiegel H, Chiegoua Dipah G, Schmitz S, Breuer G Malar J. 2021; 20(1):37.

PMID: 33430886 PMC: 7798374. DOI: 10.1186/s12936-020-03548-3.

The N-Terminal Region of MSP10 Is a Target of Protective Antibodies in Malaria and Is Important for PfGAMA/PfMSP10 Interaction.

Nagaoka H, Kanoi B, Jinoka K, Morita M, Arumugam T, Palacpac N Front Immunol. 2019; 10:2669.

PMID: 31824483 PMC: 6880778. DOI: 10.3389/fimmu.2019.02669.

References

Costa G, Loizon S, Guenot M, Mocan I, Halary F, de Saint-Basile G . Control of Plasmodium falciparum erythrocytic cycle: γδ T cells target the red blood cell-invasive merozoites. Blood. 2011; 118(26):6952-62. DOI: 10.1182/blood-2011-08-376111. View

Voepel N, Boes A, Edgue G, Beiss V, Kapelski S, Reimann A . Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants. Biotechnol J. 2014; 9(11):1435-45. DOI: 10.1002/biot.201400350. View

Stothard P . The sequence manipulation suite: JavaScript programs for analyzing and formatting protein and DNA sequences. Biotechniques. 2000; 28(6):1102, 1104. DOI: 10.2144/00286ir01. View

Blackman M, Ling I, Nicholls S, Holder A . Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol. 1991; 49(1):29-33. DOI: 10.1016/0166-6851(91)90127-r. View

Cheng X, Hayasaka H, Watanabe K, Tao Y, Liu J, Tsukamoto H . Production of high-affinity human monoclonal antibody fab fragments to the 19-kilodalton C-terminal merozoite surface protein 1 of Plasmodium falciparum. Infect Immun. 2007; 75(7):3614-20. PMC: 1932930. DOI: 10.1128/IAI.00062-07. View

Boyle M, Reiling L, Feng G, Langer C, Osier F, Aspeling-Jones H . Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015; 42(3):580-90. PMC: 4372259. DOI: 10.1016/j.immuni.2015.02.012. View

Muellenbeck M, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse C . Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med. 2013; 210(2):389-99. PMC: 3570107. DOI: 10.1084/jem.20121970. View

Spiegel H, Schinkel H, Kastilan R, Dahm P, Boes A, Scheuermayer M . Optimization of a multi-stage, multi-subunit malaria vaccine candidate for the production in Pichia pastoris by the identification and removal of protease cleavage sites. Biotechnol Bioeng. 2014; 112(4):659-67. DOI: 10.1002/bit.25481. View

Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L . Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J. 2008; 6(4):392-402. DOI: 10.1111/j.1467-7652.2008.00330.x. View

10.

Pacheco M, Elango A, Rahman A, Fisher D, Collins W, Barnwell J . Evidence of purifying selection on merozoite surface protein 8 (MSP8) and 10 (MSP10) in Plasmodium spp. Infect Genet Evol. 2012; 12(5):978-86. PMC: 4405235. DOI: 10.1016/j.meegid.2012.02.009. View

11.

Osier F, Fegan G, Polley S, Murungi L, Verra F, Tetteh K . Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008; 76(5):2240-8. PMC: 2346713. DOI: 10.1128/IAI.01585-07. View

12.

Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P . Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med. 1995; 182(2):409-18. PMC: 2192140. DOI: 10.1084/jem.182.2.409. View

13.

Miura K, Zhou H, Diouf A, Moretz S, Fay M, Miller L . Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol. 2009; 16(7):963-8. PMC: 2708396. DOI: 10.1128/CVI.00042-09. View

14.

Chappel J, Rogers W, Hoffman S, Kang A . Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J. 2004; 3:28. PMC: 509279. DOI: 10.1186/1475-2875-3-28. View

15.

Moss D, Remarque E, Faber B, Cavanagh D, Arnot D, Thomas A . Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development. Infect Immun. 2011; 80(3):1280-7. PMC: 3294643. DOI: 10.1128/IAI.05887-11. View

16.

Beiss V, Spiegel H, Boes A, Kapelski S, Scheuermayer M, Edgue G . Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein. Biotechnol Bioeng. 2015; 112(7):1297-305. DOI: 10.1002/bit.25548. View

17.

Faber B, Younis S, Remarque E, Rodriguez Garcia R, Riasat V, Walraven V . Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines. Infect Immun. 2013; 81(5):1479-90. PMC: 3648017. DOI: 10.1128/IAI.01267-12. View

18.

Doria-Rose N, Schramm C, Gorman J, Moore P, Bhiman J, DeKosky B . Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509(7498):55-62. PMC: 4395007. DOI: 10.1038/nature13036. View

19.

Richards J, Beeson J . The future for blood-stage vaccines against malaria. Immunol Cell Biol. 2009; 87(5):377-90. DOI: 10.1038/icb.2009.27. View

20.

Kim S, Hwang S, Lee Y, Choi I, Park S, Kho W . Single-chain antibody fragment specific for Plasmodium vivax Duffy binding protein. Clin Vaccine Immunol. 2007; 14(6):726-31. PMC: 1951088. DOI: 10.1128/CVI.00456-06. View